|
1
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Jemal A, Siegel R, Ward E, Hao Y, Xu J,
Murray T and Thun MJ: Cancer statistics, 2008. CA Cancer J Clin.
58:71–96. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Molina JR, Yang P, Cassivi SD, Schild SE
and Adjei AA: Non-small cell lung cancer: Epidemiology, risk
factors, treatment, and survivorship. Mayo Clin Proc. 83:584–594.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lynch TJ, Bell DW, Sordella R,
Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat
SM, Supko JG, Haluska FG, et al: Activating mutations in the
epidermal growth factor receptor underlying responsiveness of
non-small-cell lung cancer to gefitinib. N Engl J Med.
350:2129–2139. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Paez JG, Jänne PA, Lee JC, Tracy S,
Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ, et
al: EGFR mutations in lung cancer: Correlation with clinical
response to gefitinib therapy. Science. 304:1497–1500. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Pao W, Miller V, Zakowski M, Doherty J,
Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L, et al:
EGF receptor gene mutations are common in lung cancers from ‘never
smokers’ and are associated with sensitivity of tumors to gefitinib
and erlotinib. Proc Natl Acad Sci USA. 101:13306–13311. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Shigematsu H, Lin L, Takahashi T, Nomura
M, Suzuki M, Wistuba II, Fong KM, Lee H, Toyooka S, Shimizu N, et
al: Clinical and biological features associated with epidermal
growth factor receptor gene mutations in lung cancers. J Natl
Cancer Inst. 97:339–346. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Wu JY, Yu CJ, Chang YC, Yang CH, Shih JY
and Yang PC: Effectiveness of tyrosine kinase inhibitors on
‘uncommon’ epidermal growth factor receptor mutations of unknown
clinical significance in non-small cell lung cancer. Clin Cancer
Res. 17:3812–3821. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yasuda H, Kobayashi S and Costa DB: EGFR
exon 20 insertion mutations in non-small-cell lung cancer:
Preclinical data and clinical implications. Lancet Oncol.
13:e23–e31. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Yasuda H, Park E, Yun CH, Sng NJ,
Lucena-Araujo AR, Yeo WL, Huberman MS, Cohen DW, Nakayama S,
Ishioka K, et al: Structural, biochemical, and clinical
characterization of epidermal growth factor receptor (EGFR) exon 20
insertion mutations in lung cancer. Sci Transl Med. 5:216ra1772013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Travis WD, Brambilla E, Burke AP, Marx A
and Nicholson AG: Adenocarcinoma. WHO Classification of Tumours of
the Lung, Pleura, Thymus and Heart. 7:(4th). (Lyon). IARC Press.
26–37. 2015.
|
|
12
|
Kosaka T, Yatabe Y, Endoh H, Kuwano H,
Takahashi T and Mitsudomi T: Mutations of the epidermal growth
factor receptor gene in lung cancer: Biological and clinical
implications. Cancer Res. 64:8919–8923. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang SF, Liu HP, Li LH, Ku YC, Fu YN,
Tsai HY, Chen YT, Lin YF, Chang WC, Kuo HP, et al: High frequency
of epidermal growth factor receptor mutations with complex patterns
in non-small cell lung cancers related to gefitinib responsiveness
in Taiwan. Clin Cancer Res. 10:8195–8203. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Tokumo M, Toyooka S, Kiura K, Shigematsu
H, Tomii K, Aoe M, Ichimura K, Tsuda T, Yano M, Tsukuda K, et al:
The relationship between epidermal growth factor receptor mutations
and clinicopathologic features in non-small cell lung cancers. Clin
Cancer Res. 11:1167–1173. 2005.PubMed/NCBI
|
|
15
|
Han SW, Kim TY, Hwang PG, Jeong S, Kim J,
Choi IS, Oh DY, Kim JH, Kim DW, Chung DH, et al: Predictive and
prognostic impact of epidermal growth factor receptor mutation in
non-small-cell lung cancer patients treated with gefitinib. J Clin
Oncol. 23:2493–2501. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Mitsudomi T, Kosaka T, Endoh H, Horio Y,
Hida T, Mori S, Hatooka S, Shinoda M, Takahashi T and Yatabe Y:
Mutations of the epidermal growth factor receptor gene predict
prolonged survival after gefitinib treatment in patients with
non-small-cell lung cancer with postoperative recurrence. J Clin
Oncol. 23:2513–2520. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tsao MS, Sakurada A, Cutz JC, Zhu CQ,
Kamel-Reid S, Squire J, Lorimer I, Zhang T, Liu N, Daneshmand M, et
al: Erlotinib in lung cancer - molecular and clinical predictors of
outcome. N Engl J Med. 353:133–144. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kancha RK, von Bubnoff N, Peschel C and
Duyster J: Functional analysis of epidermal growth factor receptor
(EGFR) mutations and potential implications for EGFR targeted
therapy. Clin Cancer Res. 15:460–467. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chen YR, Fu YN, Lin CH, Yang ST, Hu SF,
Chen YT, Tsai SF and Huang SF: Distinctive activation patterns in
constitutively active and gefitinib-sensitive EGFR mutants.
Oncogene. 25:1205–1215. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wu JY, Wu SG, Yang CH, Gow CH, Chang YL,
Yu CJ, Shih JY and Yang PC: Lung cancer with epidermal growth
factor receptor exon 20 mutations is associated with poor gefitinib
treatment response. Clin Cancer Res. 4:4877–4882. 2008. View Article : Google Scholar
|
|
21
|
Beau-Faller M, Prim N, Ruppert AM,
Nanni-Metéllus I, Lacave R, Lacroix L, Escande F, Lizard S, Pretet
JL, Rouquette I, et al: Rare EGFR exon 18 and exon 20 mutations in
non-small-cell lung cancer on 10 117 patients: A multicentre
observational study by the French ERMETIC-IFCT network. Ann Oncol.
25:126–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shih JY, Gow CH and Yang PC: EGFR mutation
conferring primary resistance to gefitinib in non-small-cell lung
cancer. N Engl J Med. 353:207–208. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Pugh TJ, Bebb G, Barclay L, et al:
Correlations of EGFR mutations and increases in EGFR and HER2 copy
number to gefitinib response in a retrospective analysis of lung
cancer patients. BMC Cancer. 7:1282007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Weber B, Hager H, Sorensen BS, McCulloch
T, Mellemgaard A, Khalil AA, Nexo E and Meldgaard P: EGFR mutation
frequency and effectiveness of erlotinib: A prospective
observational study in Danish patients with non-small cell lung
cancer. Lung Cancer. 83:224–230. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Masago K, Fujita S, Irisa K, Kim YH,
Ichikawa M, Mio T and Mishima M: Good clinical response to
gefitinib in a non-small cell lung cancer patient harboring a rare
somatic epidermal growth factor gene point mutation; codon 768 AGC
> ATC in exon 20 (S768I). Jpn J Clin Oncol. 40:1105–1109. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Szumera-Ciećkiewicz A, Olszewski WT,
Tysarowski A, et al: EGFR mutation testing on cytological and
histological samples in non-small cell lung cancer: A Polish,
single institution study and systematic review of European
incidence. Int J Clin Exp Pathol. 6:2800–2812. 2013.PubMed/NCBI
|
|
27
|
Asahina H, Yamazaki K, Kinoshita I,
Yokouchi H, Dosaka-Akita H and Nishimura M: Non-responsiveness to
gefitinib in a patient with lung adenocarcinoma having rare EGFR
mutations S768I and V769L. Lung Cancer. 54:419–422. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Pallan L, Taniere P and Koh P: Rare EGFR
exon 20 S768I mutation predicts resistance to targeted therapy: A
report of two cases. J Thorac Oncol. 9:e752014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kobayashi S, Canepa HM, Bailey AS,
Nakayama S, Yamaguchi N, Goldstein MA, Huberman MS and Costa DB:
Compound EGFR mutations and response to EGFR tyrosine kinase
inhibitors. J Thorac Oncol. 8:45–51. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Han SW, Kim TY, Lee KH, et al: Clinical
predictors versus epidermal growth factor receptor mutation in
gefitinib-treated non-small-cell lung cancer patients. Lung Cancer.
54:201–207. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Takano T, Ohe Y, Sakamoto H, et al:
Epidermal growth factor receptor gene mutations and increased copy
numbers predict gefitinib sensitivity in patients with recurrent
non-small-cell lung cancer. J Clin Oncol. 23:6829–6837. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Greulich H, Chen TH, Feng W, Jänne PA,
Alvarez JV, Zappaterra M, Bulmer SE, Frank DA, Hahn WC, Sellers WR
and Meyerson M: Oncogenic transformation by inhibitor-sensitive and
-resistant EGFR mutants. PLoS Med. 2:e3132005. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Levkowitz G, Waterman H, Ettenberg SA,
Katz M, Tsygankov AY, Alroy I, Lavi S, Iwai K, Reiss Y, Ciechanover
A, et al: Ubiquitin ligase activity and tyrosine phosphorylation
underlie suppression of growth factor signaling by c-Cbl/Sli-1. Mol
Cell. 4:1029–1040. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Haglund K, Sigismund S, Polo S,
Szymkiewicz I, Di Fiore PP and Dikic I: Multiple monoubiquitination
of RTKs is sufficient for their endocytosis and degradation. Nat
Cell Biol. 5:461–466. 2003. View
Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mosesson Y, Shtiegman K, Katz M, Zwang Y,
Vereb G, Szollosi J and Yarden Y: Endocytosis of receptor tyrosine
kinases is driven by monoubiquitylation, not polyubiquitylation. J
Biol Chem. 78:21323–21326. 2003. View Article : Google Scholar
|
|
36
|
Pallis AG, Voutsina A, Kalikaki A,
Souglakos J, Briasoulis E, Murray S, Koutsopoulos A, Tripaki M,
Stathopoulos E, Mavroudis D and Georgoulias V: ‘Classical’ but not
‘other’ mutations of EGFR kinase domain are associated with
clinical outcome in gefitinib-treated patients with non-small cell
lung cancer. Br J Cancer. 97:1560–1566. 2007. View Article : Google Scholar : PubMed/NCBI
|
